What's New
Pave the Path Forward This Giving Tuesday
AFTD Persons with FTD Advisory Council member Sandy Howe and her husband, Dirk, are sharing their story this Giving Tuesday to raise awareness about FTD and provide support for other…
Love Will End FTD: Katie Brandt on Caregiving, Loss, and Leading Change
Katie Brandt, an active and longtime AFTD volunteer, was interviewed on the podcast Navigating the World With Your Aging Loved One. She spoke with host Nicole Will about what it…
Finding Your Way Through the Holidays with FTD
The holidays can magnify everything about living with FTD, but can also become opportunities to adapt and create new ways for connection. For families navigating FTD, the key isn’t trying…
AFTD Webinars: Supporting FTD Care Partners with Individual Therapy
Caring for a family member with FTD can profoundly impact one’s emotional and mental well-being. Care partners are therefore often encouraged to prioritize self-care, including by seeking individual therapy. But…
Study Investigates if Clinical PSP Diagnoses Match Neuropathology in a National Dataset
A study published in the medical journal Alzheimer’s & Dementia finds disagreement between progressive supranuclear palsy (PSP) diagnoses made in-clinic and brain autopsies in the National Alzheimer’s Coordinating Center’s (NACC)…
Rev. Jesse Jackson, Civil Rights Leader, Diagnosed with PSP
The FTD community extends its heartfelt support to Rev. Jesse Jackson and his family following the news today that the civil rights icon has been diagnosed with progressive supranuclear palsy…
Vanity Fair Features Soho Sessions AFTD Benefit in Honor of Bruce Willis
A Soho Sessions benefit concert for AFTD was the subject of an article in Vanity Fair this week. The event, held November 5, honored Bruce Willis, currently living with an…
Amylyx Pharmaceuticals Ends PSP Trial of AMX0035
Amylyx Pharmaceuticals announced recently that it would end its phase 2b trial of its drug AMX0035 for the treatment of progressive supranuclear palsy (PSP). The trial will not proceed to…
Tenacious AFTD Advocacy Gaining Momentum
With 2025’s FTD Awareness Week now behind us, AFTD’s Advocacy team is already gearing up its efforts for next year and beyond. The goal: to have official recognition of FTD…
Alector Clinical Trial Results Townhall
On October 21, 2025, results from Alector Therapeutics’ Phase 3 clinical trial for Latozinemab (AL001) were announced. This intervention, designed for people with FTD caused by variants in the GRN…
